CNMDCONMED Corporation
Is the price fair?
Undemanding: cheap against its own history and cheap vs its sector.
Cheap vs its own history: P/E 24.0 vs a 49.1 median over 33 quarters (−51% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What CNMD's price assumes
CONMED Corporation trades at 24.0× earnings against 26.2× for the median Medical Devices name, cheaper than its own group.
Trailing P/E · Medical Devices median 26.2 · cheaper than the typical name in its group
- Price / sales
- 0.76
Price / sales · today's price, trailing year to Jun 30, 2026
- Price / book
- 1.00
Price / book · today's price, trailing year to Jun 30, 2026
- EV / sales
- 1.34
EV / sales
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 1.00
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 16.7
- EV / salestoday's price, trailing year to Jun 30, 2026
- 1.34
- Healthcare median P/E509 names
- 26.2
- Medical Devices median P/E64 names
- 26.2
- Market capitalisation
- $1.04B
| Method | Per share |
|---|---|
| What its own history would imply | not meaningful, 24.0× today against a 49.1× median |
| 52-week range | $32.11 – $51.88 |
| Today | $44.43 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.